GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price fell 8.8% during trading on Thursday. The stock traded as low as $3.11 and last traded at $3.0640. Approximately 861,284 shares were traded during trading, a decline of 52% from the average session volume of 1,808,294 shares. The stock had previously closed at $3.36.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. Citigroup increased their price target on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. TD Cowen boosted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Barclays increased their target price on GoodRx from $3.00 to $4.00 and gave the stock an "underweight" rating in a research note on Thursday, August 20th. The Goldman Sachs Group reissued a "neutral" rating and issued a $4.00 price target on shares of GoodRx in a report on Friday, August 7th. Finally, Wells Fargo & Company raised their price target on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $4.15.
Check Out Our Latest Stock Analysis on GoodRx
GoodRx Stock Down 9.7%
The firm has a 50 day moving average of $3.44 and a two-hundred day moving average of $2.89. The stock has a market capitalization of $1.04 billion, a PE ratio of 75.89 and a beta of 1.66. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74.
Insiders Place Their Bets
In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 1,841,761 shares of company stock worth $6,432,783 in the last quarter. Corporate insiders own 5.87% of the company's stock.
Institutional Trading of GoodRx
A number of institutional investors have recently added to or reduced their stakes in GDRX. Essential Partners LLC increased its stake in shares of GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock worth $28,000 after buying an additional 11,295 shares during the last quarter. Headlands Technologies LLC bought a new stake in GoodRx during the second quarter valued at $30,000. Focus Advisor Solutions LLC acquired a new stake in shares of GoodRx during the third quarter worth $33,000. R Squared Ltd acquired a new stake in shares of GoodRx during the third quarter worth $36,000. Finally, Amundi acquired a new stake in shares of GoodRx during the first quarter worth $37,000. 63.77% of the stock is owned by hedge funds and other institutional investors.
About GoodRx
(
Get Free Report)
GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.